Pramipexole Dihydrochloride



Pramipexole Dihydrochloride





(pram ah pex’ ole)

Mirapex, Mirapex ERDNC

PREGNANCY CATEGORY C


Drug Classes

Antiparkinsonian

Dopamine receptor agonist


Therapeutic Actions

Stimulates dopamine receptors in the striatum, leading to decrease in parkinsonian symptoms thought to be related to low dopamine levels.


Indications



  • Treatment of the signs and symptoms of idiopathic Parkinson disease


  • Treatment of moderate to severe primary restless legs syndrome (Mirapex)


  • Unlabeled use: Treatment of fibromyalgia



Available Forms

Tablets—0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tabletsDNC—0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg


Dosages

Adults



  • Parkinson disease: Increase dosage gradually from a starting dose of 0.125 mg PO tid for 1 wk; wk 2—0.25 mg PO tid; wk 3—0.5 mg PO tid; wk 4—0.75 mg PO tid; wk 5—1 mg PO tid; wk 6—1.25 mg PO tid; wk 7—1.5 mg PO tid. Once levels are established, ER tablets may be used for once-a-day dosing. If used in combination with levodopa, consider levodopa dose reduction.


  • Restless leg syndrome: Initially, 0.125 mg/day PO taken 2–3 hr before bedtime; dose may be increased every 4–7 days, if needed, to 0.25 mg/day and maximum of 0.5 mg/day.

Pediatric patients

Safety and efficacy not established.

Patients with renal impairment



























CrCl (mL/min) Starting Dose Maximum Dose
More than 60 0.125 mg PO tid 1.5 mg PO tid
35–59 0.125 mg PO bid 1.5 mg PO bid
15–34 0.125 mg PO daily 1.5 mg PO daily
Less than 15 Safety and efficacy not established; data not available  

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Pramipexole Dihydrochloride

Full access? Get Clinical Tree

Get Clinical Tree app for offline access